Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)

Introduction: Monoclonal antibodies (mAbs) targeting immunoglobulin E (IgE) [omalizumab], type 2 (T2) cytokine interleukin (IL) 5 [mepolizumab, reslizumab], IL-4 Receptor (R) α [dupilumab], and IL-5R [benralizumab]), improve quality of life in patients with T2-driven inflammatory diseases. However,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in pharmacology Jg. 14; S. 1276340
Hauptverfasser:	Pera, Victor, Brusselle, Guy G., Riemann, Sebastian, Kors, Jan A., Van Mulligen, Erik M., Parry, Rowan, de Wilde, Marcel, Rijnbeek, Peter R., Verhamme, Katia M. C.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Frontiers Media S.A 14.11.2023
Schlagworte:	biologicals disproportionality analysis FAERS monoclonal antibodies parasitic infections Pharmacology spontaneous reporting
ISSN:	1663-9812, 1663-9812
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!